[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

634.O2.6 634. Myeloproliferative Syndromes: Clinical Advances I

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 12, 2011: 7:00 AM-8:30 AM
Room 6B (San Diego Convention Center)
Ruben A. Mesa, MD, Mayo Clinic and Mary Frances McMullin, MD, Queens University of Belfast

Mesa: Incyte: Research Funding; Lilly: Research Funding; SBio: Research Funding; Astra Zeneca: Research Funding; NS Pharma: Research Funding; Celgene: Research Funding. McMullin: Novartis : Honoraria; Cellgene: Honoraria; Pzifer: Honoraria.
7:00 AM
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International StudyClinically Relevant Abstract

Ayalew Tefferi, MD1, Elisa Rumi2*, Guido Finazzi, MD3*, Alessandro M. Vannucchi, MD4, Maria Luigia Randi5*, Ilaria Nichele6*, Heinz Gisslinger, MD7, Rakhee Vaidya, MD8*, Mario Cazzola9, Alessandro Rambaldi10, Lisa Pieri, MD11*, Francesco Rodeghiero, MD12, Irene Bertozzi5*, Bettina Gisslinger7*, Animesh Pardanani, MBBS, PhD1, Juergen Thiele13*, Francesco Passamonti, MD14* and Tiziano Barbui, MD3*

1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
2Department of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
3USC Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy
4Hematology, University of Florence, Florence, Italy
5University of Padua, Italy
6Hematology, S. Bortolo Hospital, Vicenza, Italy
7Department for Internal Medicine I, Medical University of Vienna, Vienna, Austria
8Hematology, Mayo Clinic, Rochester, MN
9Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
10Div of Hematology, Ospedali Riuniti, Bergamo, Italy
11Dept of Medical and Surgical Care, Hematology, University of Florence, Florence, Italy
12Department of Hematology, San Bortolo Hospital, Vicenza, Italy
13University of Cologne, Germany, Cologne, Germany
14Hematology, Ospedale di Circulo e Fondazione Macchi , Varese, Italy

7:15 AM
Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-IClinically Relevant Abstract

Srdan Verstovsek, MD, PhD1, Ruben A. Mesa, MD2, Jason Gotlib, MD, MS3, Richard S. Levy, MD4*, Vikas Gupta, MD, FRCP, FRCPath5, John F. DiPersio, MD, PhD6, John Catalano, MD7, Michael W. Deininger8, Carole B. Miller, MD9*, Richard T. Silver, MD10, Moshe Talpaz, MD11, Elliott F. Winton, MD12, Jimmie H. Harvey Jr., MD13*, Murat O. Arcasoy, MD14, Elizabeth Hexner, MD15, Roger M. Lyons, MD16, Ronald Paquette, MD, PhD17*, Azra Raza, MD18, Kris Vaddi, PhD4*, Sue Erickson-Viitanen, PhD4*, William Sun, PhD4*, Victor A. Sandor, MD, CM4* and Hagop M. Kantarjian1

1University of Texas MD Anderson Cancer Center, Houston, TX
2Mayo Clinic, Scottsdale, AZ
3Medicine/Hematology, Stanford University Cancer Institute, Stanford, CA
4Incyte Corporation, Wilmington, DE
5Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, ON, Canada
6Washington University School of Medicine, St. Louis, MO
7Frankston Hospital, Frankston, Victoria, Australia
8University of Utah Huntsman Cancer Institute, Salt Lake City, UT
9Saint Agnes Cancer Institute, Baltimore, MD
10Weill Medical College of Cornell University, New York, NY
11University of Michigan, Ann Arbor, MI
12Emory University School of Medicine, Atlanta, GA
13Birmingham Hematology & Oncology Associates, Birmingham, AL
14Duke University Health System, Durham, NC
15Abramson Cancer Center at The University of Pennsylvania, Philadelphia, PA
16Cancer Care Centers of South Texas/US Oncology, San Antonio, TX
17UCLA Medical Hematology & Oncology, Los Angeles, CA
18Columbia Presbyterian Medical Center, New York, NY

7:30 AM
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II StudyClinically Relevant Abstract

Claire N. Harrison, DM, FRCP, FRCPath1, Jean-Jacques Kiladjian, MD, PhD2, Heinz Gisslinger, MD3, Dietger Niederwieser, MD4, Francesco Passamonti, MD5*, Roger J. Waltzman, MD6, Norbert Hollaender, PhD7*, Deborah S. Hunter, PhD8*, Richard S. Levy, MD8*, Laurent Knoops, MD, PhD9*, Francisco Cervantes, MD, PhD10, Alessandro M. Vannucchi, MD11, Tiziano Barbui, MD12* and Giovanni Barosi, MD13

1Dept. of Haematology, Guy's and St. Thomas NHS FoundationTrust, London, United Kingdom
2Centre d'Investigation Clinique (CIC), Hôpital Saint-Louis, Paris, France
3Medical University of Vienna, Vienna, Austria
4University of Leipzig, Leipzig, Germany
5Depèartment of Internal Medicine, Fondazione Macchi, Division of Hematology, Varese, Italy
6Novartis Pharmaceuticals Corporation, East Hanover, NJ
7Novartis Oncology (INC424), Biometrics & Data Management (BDM), Novartis Pharma AG, Basel, Switzerland
8Incyte Corporation, Wilmington, DE
9Cliniques univeristaires Saint-Luc and Ludwig Institute for Cancer Research, Brussels, Belgium
10Hematology Department, Hospital Clínic, Barcelona, Spain
11Department of Clinical Care, UF Hematology, University of Florence, Florence, Italy
12A.O. Ospedali Riuniti di Bergamo, Bergamo, Italy
13IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

7:45 AM
Complete Hematological, Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon α-2a (peg-IFNα-2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 TrialClinically Relevant Abstract

Pascal Turlure, MD1*, Nathalie Cambier, MD2*, Murielle Roussel3*, Sylvia Bellucci, MD, PhD4, Jean-Marc Zini, MD, PhD5*, Jean-Didier Rain, MD5*, Philippe Rousselot, MD, PhD6*, William Vainchenker, MD, PhD7, Lina Abdelkader8*, Kamel Ghomari9*, Jean-Luc Dutel9*, Yasmine Chait10*, Sylvie Chevret11*, Christine Chomienne, MD, PhD12*, Bruno Cassinat, PharmD13* and Jean-Jacques Kiladjian, MD, PhD14,15

1Service d'Hématologie Clinique, CHU, Limoges, France
2Service d'Hématologie, CHRU Lille, Lille, France
3Hématologie Clinique, Hôpital Purpan, Toulouse, France
4Biological Hematology, Hopital Lariboisiere, Paris, France
5Hôpital Saint-Louis, Paris, France
6 , Hopital de Versailles. Université Versailles Saint Quentin en Yvelines, Le Chesnay, France
7INSERM U1009, Institut Gustave Roussy, Université Paris XI, Villejuif, France
8CH Chartres, France
9Service d'Hématologie, CH Beauvais, Beauvais, France
10Service d'Hématologie, CH Montfermeil, Montfermeil, France
11Biostatistics, Hôpital Saint-Louis, AP-HP, Université Paris 7, Paris, France
12Institut Universitaire d'Hématologie, INSERM UMR-S 940, Paris, France
13Unite de Biologie Cellulaire, Hopital Saint-Louis, Paris, France
14Centre d'Investigation Clinique (CIC), Hôpital Saint-Louis, Paris, France
15French Intergroup of Myeloproliferative disorders (FIM), Paris, France

8:00 AM
Dynamics of Mutant Alleles in Patients with Advanced Essential Thrombocythemia (ET) or Polycythemia (PV) During Pegylated Interferon-Alfa-2A (PEG-IFN-α-2A; Pegasys) TherapyClinically Relevant Abstract

Alfonso Quintas-Cardama, MD1, Omar Abdel-Wahab, MD2, Ross L Levine, MD3, Taghi Manshouri, PhD4*, Anne-Laure Roupie5*, Hagop M. Kantarjian6 and Srdan Verstovsek, MD, PhD4

1Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York City, NY
3Human Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
5Universite Paris Descartes, Paris, France
6Leukemia Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX

8:15 AM
Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia MyelofibrosisClinically Relevant Abstract

Rami S. Komrokji, MD1, Martha Wadleigh, MD2*, John F. Seymour, MD, PhD3*, Andrew W. Roberts, MD, PhD4*, Luen Bik To5, Huan J. Zhu, MD, PhD6 and Ruben A. Mesa, MD7

1Hematologic Malignancies, Moffitt Cancer Center, Tampa, FL
2Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Department for the Haematology Tumour Stream, Peter MacCallum Cancer Institute, Victoria, Australia
4Department of Clinical Haematology and Medical Oncology, The Royal Melbourne Hospital, Parkville, Australia
5Department of Haematology, IMVS, Adelaide, Australia
6Global Clinical Development, SBIO, Inc., Redwood City, CA
7Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ

*signifies non-member of ASH